Open AccessHER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Author(s) -
A. Prat,
T. Pascual,
C. De Angelis,
C. Gutierrez,
A. Llombart-Cussac,
T. Wang,
J. Cortés,
B. Rexer,
L. Paré,
A. Forero,
Annabell Wolff,
S. Morales,
B. Adamo,
F. Brasó-Maristany,
M. Vidal,
J. Veeraraghavan,
I. Krop,
P. Galván,
A.C. Pavlick,
B. Bermejo,
M. Izquierdo,
Vanessa Rodrik-Outmezguine,
J.S. Reis-Filho,
S.G. Hilsenbeck,
MARCOS ANTÔNIO GOMES DE OLIVEIRA,
M.V. DIeci,
G. Griguolo,
R. Fasani,
P. Nuciforo,
J.S. Parker,
P. Conte,
R. Schiff,
V. Guarneri,
C.K. Osborne,
M.F. Rimawi
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/ccpq-0s57
Subject(s) - blockade , breast cancer , dual (grammatical number) , trastuzumab , oncology , medicine , cancer research , cancer , biology , receptor , art , literature